Article Abstract

Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy

Authors: Whitney L. Guerrero, Gitonga Munene, Paxton V. Dickson, Dina Darby, Andrew M. Davidoff, Michael G. Martin, Evan S. Glazer, David Shibata, Jeremiah L. Deneve


Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program.
Methods: An IRB approved retrospective review was performed for the first 50 patients treated with CRS/ HIPEC with clinicopathologic data described.
Results: Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11–73 years). Primary pathology included: appendix (42%, n=21), ovary (18%, n=9), colon (14%, n=7), desmoplastic small round cell tumor (14%, n=7) or other (12%, n=6). The median peritoneal cancer index (PCI) score was 15.5 (range, 1–39) and 92% underwent complete cytoreduction (CCR 0/1). Median hospital length of stay was 9.0 days (range, 6–35 days). Eight patients (16%) suffered major morbidity with 2 (4%) 30-day mortalities.
Conclusions: Short-term outcomes observed after CRS/HIPEC in a newly developed center for PC are consistent with published higher volume center experiences.